Home
/
Alaunos Therapeutics, Inc.
/
Financials
/
Quarterly
Alaunos Therapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Alaunos Therapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2012
Mar 31, 2012
$200.0K
May 3, 2012
Q1
2012
Mar 31, 2011
$67.0K
May 3, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 14, 2025
Q2
2025
Jun 30, 2025
$0
Aug 14, 2025
Q1
2025
Mar 31, 2025
$2.0K
May 15, 2025
Q3
2025
Sep 30, 2024
$0
Nov 14, 2025
Q2
2025
Jun 30, 2024
$4.0K
Aug 14, 2025
Q1
2025
Mar 31, 2024
$1.0K
May 15, 2025
Q3
2024
Sep 30, 2023
$0
Nov 14, 2024
Q2
2024
Jun 30, 2023
$4.0K
Aug 14, 2024
Q1
2024
Mar 31, 2023
$0
May 15, 2024
Q3
2023
Sep 30, 2022
$2.91M
Nov 14, 2023
Q2
2023
Jun 30, 2022
$0
Aug 14, 2023
Q3
2022
Sep 30, 2021
$398.0K
Nov 14, 2022
Q3
2019
Sep 30, 2018
$146.0K
Nov 7, 2019
Q2
2019
Jun 30, 2018
$146.0K
Aug 8, 2019
Q1
2019
Mar 31, 2018
$146.0K
May 8, 2019
Q3
2018
Sep 30, 2017
$1.60M
Nov 9, 2018
Q2
2018
Jun 30, 2017
$1.60M
Aug 8, 2018
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.16M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($1.05M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($1.07M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.13M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.13M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.68M)
May 15, 2025
Q3
2024
Sep 30, 2023
($8.48M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($8.77M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($10.05M)
May 15, 2024
Q3
2023
Sep 30, 2022
($8.85M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($9.93M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($9.79M)
May 10, 2023
Q3
2022
Sep 30, 2021
($22.73M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($22.67M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($21.55M)
May 16, 2022
Q3
2021
Sep 30, 2020
($20.32M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($18.60M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($18.29M)
May 6, 2021
Q3
2020
Sep 30, 2019
($74.00M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($14.62M)
Aug 6, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($1.19M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($1.04M)
Aug 14, 2025
Q1
2025
Mar 31, 2025
($1.09M)
May 15, 2025
Q3
2025
Sep 30, 2024
($1.15M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($1.17M)
Aug 14, 2025
Q1
2025
Mar 31, 2024
($1.74M)
May 15, 2025
Q3
2024
Sep 30, 2023
($8.66M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($7.98M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($9.67M)
May 15, 2024
Q3
2023
Sep 30, 2022
($8.26M)
Nov 14, 2023
Q2
2023
Jun 30, 2022
($9.23M)
Aug 14, 2023
Q1
2023
Mar 31, 2022
($9.09M)
May 10, 2023
Q3
2022
Sep 30, 2021
($22.30M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($22.64M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($21.56M)
May 16, 2022
Q3
2021
Sep 30, 2020
($20.32M)
Nov 8, 2021
Q2
2021
Jun 30, 2020
($18.61M)
Aug 13, 2021
Q1
2021
Mar 31, 2020
($18.66M)
May 6, 2021
Q3
2020
Sep 30, 2019
($13.45M)
Nov 5, 2020
Q2
2020
Jun 30, 2019
($14.75M)
Aug 6, 2020